AI Article Synopsis
- Despite widespread vaccination, pertussis is making a comeback in areas using acellular vaccines for infants and young children due to limited and short-lived immunity.
- The inability of acellular vaccines to prevent nasal colonization and transmission of the bacteria is contributing to this resurgence.
- A workshop was held in September 2019 to explore these issues, identify knowledge gaps, and suggest solutions to improve pertussis vaccine effectiveness.
Article Abstract
Despite high vaccine coverage in many parts of the world, pertussis is resurging in a number of areas in which acellular vaccines are the primary vaccine administered to infants and young children. This is attributed in part to the suboptimal and short-lived immunity elicited by acellular pertussis vaccines and to their inability to prevent nasal colonization and transmission of the etiologic agent In response to this escalating public health concern, the National Institute of Allergy and Infectious Diseases held the workshop "Overcoming Waning Immunity in Pertussis Vaccines" in September 2019 to identify issues and possible solutions for the defects in immunity stimulated by acellular pertussis vaccines. Discussions covered aspects of the current problem, gaps in knowledge and possible paths forward. This review summarizes presentations and discussions of some of the key points that were raised by the workshop.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7454230 | PMC |
| http://dx.doi.org/10.4049/jimmunol.2000676 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!